Skin Diseases: Clinical Trials

3,556 trials for Skin Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2077 completed, 361 unknown, 330 recruiting, 278 terminated. 3556 Phase 3, 403 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33556Completed 2077, Unknown 361, Recruiting 330, Terminated 278, Active not recruiting 272, Not yet recruiting 126, Withdrawn 85, Enrolling by invitation 17, Suspended 10
Phase 2403Completed 176, Unknown 76, Recruiting 45, Terminated 43, Active not recruiting 25, Not yet recruiting 16, Withdrawn 15, Enrolling by invitation 4, Suspended 3

Follow Skin Diseases: new trials by email Literature Review of Skin Diseases trials Research Report on Skin Diseases

Trials (filtered) newest first · largest first

All 3,556 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Phase 3Not yet recruitingCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal1202027-10-012026-10-30
Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer
Locoregional Radiotherapy With Internal Mammary Node Irradiation, Locoregional Radiotherapy Without Internal Mammary Node Irradiation - Breast Neoplasms
Phase 3Not yet recruitingMahidol University17602027-07-012026-11-13
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
Abrocitinib, Placebo - Atopic Dermatitis
Phase 3Not yet recruitingPfizer902027-05-012026-09-16
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis
Phase 3Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company922027-02-032026-09-18
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3Not yet recruitingEurofarma Laboratorios S.A.3722027-01-312026-11-06
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)
Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer
Phase 3Not yet recruitingNRG Oncology52702027-01-302026-09-30
Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss
DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness
Phase 3WithdrawnApplied Biology, Inc.2027-01-152026-11-02
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Placebo, Zasocitinib - Psoriatic Arthritis
Phase 3Not yet recruitingTakeda6442027-01-112026-10-27
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin - Cutaneous Leihmaniasis
Phase 3Not yet recruitingInstitute of Tropical Medicine, Belgium9002027-01-012026-03-10
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
BOTOX INJECTION - Buerger Disease, Raynaud Syndrome
Phase 3Not yet recruitingUniversity Hospital, Toulouse82027-01-012026-07-23
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3Not yet recruitingEurofarma Laboratorios S.A.3722027-01-012026-11-04
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 3Not yet recruitingBristol-Myers Squibb23002026-12-312026-09-03
A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa
Neolizumab - Dystrophic Epidermolysis Bullosa
Phase 2 / Phase 3Not yet recruitingCentre Hospitalier Universitaire de Nice152026-12-312026-11-09
Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan
Dexamethasone, antiemetic premedication, T-DXd - Breast Cancer, Interstitial Lung Disease (ILD)
Phase 3Not yet recruitingMario Negri Institute for Pharmacological Research2442026-12-202026-10-19
A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.
ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis
Phase 2 / Phase 3Not yet recruitingAbbVie5802026-12-112026-11-12
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma
Phase 3Not yet recruitingScancell Ltd5502026-12-012026-09-11
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial
Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia
Phase 2 / Phase 3Not yet recruitingSherief Ayman Hussein Shaamash402026-12-012026-10-07
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
Phase 3Not yet recruitingPfizer38002026-12-012026-11-10
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
BCS + SRG-514, BCS - TNBC - Triple-Negative Breast Cancer
Phase 3Not yet recruitingSURGE Therapeutics4002026-12-012026-11-12
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin) - Triple Negative Breast Cancer
Phase 3Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.5502026-11-302026-10-19

Showing 20 of 3556. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (1274)  ·  Psoriasis (265)  ·  Dermatitis, Atopic (236)  ·  Melanoma (181)  ·  Acne Vulgaris (138)  ·  Arthritis, Psoriatic (105)  ·  Triple Negative Breast Neoplasms (100)  ·  Neoplasm Metastasis (89)  ·  Eczema (85)  ·  Pruritus (85)  ·  Keratosis, Actinic (78)  ·  Diabetic Foot (73)  ·  Neoplasms (65)  ·  Angioedemas, Hereditary (60)

Broader conditions

Skin and Connective Tissue Diseases (3556)  ·  Neoplasms (1603)  ·  Neoplasms by Site (1557)  ·  Breast Diseases (1338)  ·  Pathological Conditions, Signs and Symptoms (627)  ·  Immune System Diseases (545)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (421)  ·  Genetic Diseases, Inborn (404)  ·  Hypersensitivity (380)  ·  Hypersensitivity, Immediate (376)  ·  Pathologic Processes (374)  ·  Skin Diseases, Papulosquamous (368)  ·  Infections (324)  ·  Skin Diseases, Genetic (317)

Interventions

Cyclophosphamide (194)  ·  Paclitaxel (167)  ·  Docetaxel (154)  ·  Capecitabine (135)  ·  Trastuzumab (129)  ·  Tamoxifen (114)  ·  Letrozole (101)  ·  Epirubicin (96)  ·  Doxorubicin (83)  ·  Anastrozole (73)  ·  exemestane (72)  ·  Fluorouracil (70)  ·  Fulvestrant (69)  ·  Carboplatin (68)  ·  Radiotherapy (68)

Sponsors

Novartis Pharmaceuticals (130)  ·  Pfizer (73)  ·  Hoffmann-La Roche (72)  ·  Eli Lilly and Company (56)  ·  Amgen (52)  ·  Fudan University (52)  ·  AstraZeneca (50)  ·  AbbVie (49)  ·  Merck Sharp & Dohme LLC (45)  ·  Galderma R&D (43)  ·  Alliance for Clinical Trials in Oncology (39)  ·  GlaxoSmithKline (38)  ·  Bristol-Myers Squibb (35)  ·  Assistance Publique - Hôpitaux de Paris (33)  ·  Sanofi (30)

Countries

United States (1512)  ·  Canada (777)  ·  Germany (777)  ·  France (704)  ·  Spain (634)  ·  United Kingdom (616)  ·  Italy (588)  ·  China (577)  ·  Poland (569)  ·  Australia (468)  ·  Belgium (397)  ·  Hungary (392)  ·  Japan (384)  ·  South Korea (358)  ·  Czechia (340)

Results publications

PMID 38979716, PMID 34037241, PMID 36326435, PMID 29522361, PMID 39588375, PMID 32816215, PMID 37316690, PMID 37906417, PMID 33826132, PMID 38446397, PMID 40207789, PMID 42162528, PMID 35305260, PMID 40600584, PMID 40993471, PMID 30739254, PMID 31667790, PMID 32450725, PMID 33283264, PMID 34406619, PMID 36255569, PMID 36723913, PMID 36754548, PMID 37341961, PMID 38488975, PMID 38896380, PMID 39120849, PMID 39578348, PMID 40028832, PMID 40875187, PMID 41060492, PMID 41800601, PMID 20818886, PMID 22417254, PMID 23312695, PMID 26101239, PMID 27573260, PMID 27576559, PMID 31054118, PMID 31066001, PMID 32184277, PMID 33165005, PMID 33453450, PMID 34110605, PMID 34142350, PMID 34795065, PMID 34921669, PMID 35544084, PMID 35636689, PMID 36039153

NIH funding

2023 (96), 2016 (48), 2014 (43), 2018 (42), 2019 (38), 2017 (36), 2015 (33), 2025 (26), 2005 (23), 2008 (21), 2009 (20), U10CA031946 (12), U10CA180868 (11), 2004 (10), U10CA032102 (10)